Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

96 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-30

Study Completion Date

2017-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets.

SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identiﬁed from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens \[4\]

Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood

NCT06544083

Hepatocellular Carcinoma

RECRUITING

Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma

NCT01689766

Metastatic Renal Cell Carcinoma

COMPLETED PHASE2

Analysis of Expression of Specific Markers in Hepatocellular Carcinoma

NCT00858000

Hepatocellular Carcinoma

COMPLETED

Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer

NCT02879968

Head and Neck Cancer

COMPLETED

Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma

NCT02732665

Carcinoma, Renal Cell

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Role of Serum Regucalcin in Diagnosis of HCC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with HCC

serum regucalcin antibody

Intervention Type DIAGNOSTIC_TEST

serum regucalcin antibody

patients with hepatitis C Ab positive

serum regucalcin antibody

Intervention Type DIAGNOSTIC_TEST

serum regucalcin antibody

patients with hepatitis C Ab negative

serum regucalcin antibody

Intervention Type DIAGNOSTIC_TEST

serum regucalcin antibody

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum regucalcin antibody

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy)
2. Adult patients
3. Both genders are eligible.
4. Informed consent obtained from subject or subject's legal representative